By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

InDex Pharmaceuticals AB 

Scheeles väg 2

Stockholm    SE-171 77  Sweden
Phone: 46-8-50884730 Fax: 46-8-50884739


SEARCH JOBS


Key Statistics


Email: info@indexpharmab.com
Ownership: Private

Web Site: InDex Pharmaceuticals AB
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
InDex Pharmaceuticals AB Appoints Uli Hacksell And Jesper Wiklund To Its Board Of Directors 7/9/2015 8:36:05 AM
InDex Pharmaceuticals AB Regains European Rights To Kappaproct In Ulcerative Colitis 6/30/2015 9:39:19 AM
Peter Zerhouni New CEO Of InDex Pharmaceuticals AB 2/5/2015 2:20:49 PM
InDex Pharmaceuticals AB To Present Results From The COLLECT Trial At The 10th Congress Of The European Crohn’s And Colitis Organization 2/3/2015 10:07:24 AM
InDex Pharmaceuticals AB Announces Results From COLLECT, A Clinical Trial Of Kappaproct® In The Treatment Of Moderate To Severe Ulcerative Colitis 6/27/2014 8:56:54 AM
InDex Pharmaceuticals AB Closes $20 Million Financing Round, Welcomes NeoMed As New Shareholder 2/25/2014 10:09:13 AM
InDex Pharmaceuticals AB Completes Patient Recruitment in P3 Ulcerative Colitis Study With Kappaproct 4/8/2013 11:35:35 AM
InDex Pharmaceuticals AB Granted Japanese Patent for Novel Treatment of Steroid-Resistant Inflammation 10/24/2012 10:17:21 AM
InDex Pharmaceuticals AB Strengthens IP Position for Kappaproct 9/4/2012 11:19:38 AM
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early 5/18/2009 8:56:11 AM
12
//-->